Neuroinflammation
Current trials in the Department.
| Short title | Long title | PI | Phase | Type |
|---|---|---|---|---|
| UK MS Register | The UK Multiple Sclerosis Register | Braisher, Mrs Marie | Non-commercial portfolio | |
| Safety of IxaZOmib targeting plasma cells in MS (SIZOMUS) | Safety of ixazomib targeting plasma cells in multiple sclerosis: A phase 1b randomised, double-blind, placebo-controlled trial. | Brownlee, Dr Wallace | Phase Ib | Non-commercial portfolio |
| MS-PROACTIVE | Preventing job loss using Acceptance and Commitment Therapy in Vocational Rehabilitation | Brownlee, Dr Wallace | Not Applicable | Non-commercial portfolio |
| BN42083 - OCREVUS HIGH DOSE PPMS STUDY | A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | Brownlee, Dr Wallace | Phase III | Commercial portfolio |
| SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) | A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) | Brownlee, Dr Wallace | Phase IIIb | Commercial portfolio |
| CAMELOT-MS | Cladribine tablets in Highly-Active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice | Brownlee, Dr Wallace | Not Applicable | Commercial non-portfolio |
| Misdiagnosis of MS in the UK | Misdiagnosis of MS in the UK | Brownlee, Dr Wallace | Not Applicable | Non-commercial non-portfolio |
| Dynamics of grey matter & white matter pathology in multiple sclerosis | The dynamics and clinical relevance of grey matter and periventricular white matter pathology in multiple sclerosis | Chard, Dr Declan | Not Applicable | Non-commercial portfolio |
| MN39158 - A Long Term Extension Study in Multiple Sclerosis | A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL | Chataway, Prof Jeremy | Phase III | Commercial portfolio |
| OCTOPUS - Optimal Clinical Trials Platform for Progressive Multiple Sclerosis | A multicentre, interventional, multi-arm, multi-stage trial including randomisation, double blinding, placebo control evaluation of treatments for slowing the progression of disability in participants with Secondary Progressive Multiple Sclerosis (SPMS) and Primary Progressive Multiple Sclerosis (PPMS), together termed Progressive Multiple Sclerosis (PMS) | Chataway, Prof Jeremy | Phase III | Non-commercial portfolio |
| To evaluate safety and efficacy of ION373 in Alexander Disease | A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander Disease | Chataway, Prof Jeremy | Phase IIa | Commercial portfolio |
| MS-NIRS | Near-infrared spectroscopy to investigate cortical oxygenation and metabolism in multiple sclerosis – an observational cohort pilot study (student study) | Chataway, Prof Jeremy | Non-commercial non-portfolio | |
| MS-Bio | Blood Biomarkers in Multiple Sclerosis – a non interventional cohort study (Student Study) | Chataway, Prof Jeremy | Non-commercial non-portfolio | |
| StarMS | A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis. | Ciccarelli, Prof Olga | Non-commercial portfolio | |
| PITMS | Predicting Individual Treatment responses towards personalised medicine in Multiple Sclerosis | Ciccarelli, Prof Olga | Not Applicable | Non-commercial portfolio |
| MS and COVID-19 (COVID-19) (Covid, Covid-19 , Coronavirus) | Towards understanding the risk of SARS-CoV-2 infection and immune response to COVID-19 vaccines in individuals with immune-mediated conditions | Ciccarelli, Prof Olga | Not Applicable | Non-commercial non-portfolio |
| To study clinical radiological and genetic predictors of outcome in MS | Understanding the relationship between genotype and neurodegeneration in response to disease modifying treatments in multiple sclerosis: A pilot exploratory study employing high-dimensional inference of existing datasets. | Ciccarelli, Prof Olga | Non-commercial non-portfolio | |
| ORATORIO HAND | A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | De Angelis, Dr Floriana | Phase III | Commercial portfolio |
| Sodium Accumulation in Multiple sclerosis | In vivo quantification of tissue sodium (23Na) content in the brain and spinal cord in Multiple Sclerosis | Solanky, Dr Bhavana | Non-commercial portfolio | |
| A new prospective Study in Clinically Isolated Syndrome | A new prospective Clinical, Genetic and Imaging study of patients with Clinically Isolated Syndrome (CIS). | Toosy, Dr Ahmed | Non-commercial portfolio | |
| Neuroimmunology 1.4 | Investigation of autoimmunity and its effects on the brain 1.4 | Zandi, Dr Michael | Not Applicable | Non-commercial portfolio |
| IVIG and rituximab in antibody-associated psychosis - SINAPPS2 | A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2) | Zandi, Dr Michael | Phase II | Non-commercial portfolio |